Home › Funds › Lion Point Capital, LP › SNDX

Lion Point Capital, LP position in SNDX

SYNDAX PHARMACEUTICALS INC · Health Care

Lion Point Capital, LP reported holding 36,000 shares of SNDX (SYNDAX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$787K, representing 3.76% of its reported portfolio and ranking #9 among its reported holdings. Lion Point Capital, LP has disclosed SNDX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)36.00K sh
Reported value held$786.96K
Portfolio Weight3.76%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Lion Point Capital, LP's SNDX position evolved

Lion Point Capital, LP first disclosed a stake in SNDX in Q3 2023 at 34,500 shares (US$501K). The position peaked in Q1 2024 at 65,000 shares, worth US$1.5M. Across 12 filings, Lion Point Capital, LP increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 36,000 shares valued at US$787K. Notable position changes include a 88% increase in Q1 2024 (shares fell 14% over the following quarter), a 29% trim in Q3 2024 (shares fell 31% over the following quarter), a 35% trim in Q4 2025 (shares rose 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 34.50K $500.94K New
Q4 2023 34.50K $745.54K Hold
Q1 2024 65.00K $1.55M Add
Q2 2024 65.00K $1.33M Hold
Q3 2024 46.20K $889.35K Reduce
Q4 2024 55.00K $727.10K Add
Q1 2025 55.00K $675.67K Hold
Q2 2025 55.00K $515.08K Hold
Q3 2025 55.00K $846.17K Hold
Q4 2025 36.00K $756.36K Reduce
Q1 2026 36.00K $840.96K Hold
Q2 2026 36.00K $786.96K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SNDX and 13F data

SNDX (SYNDAX PHARMACEUTICALS INC) is a Health Care company. 43 other funds we track also report a position in SNDX — the largest reported positions include Kynam Capital Management, LP (US$176.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$82.6M), Eversept Partners, LP (US$61.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SNDX

All SNDX fund holders →

FAQ

How long has Lion Point Capital, LP held SNDX?

Lion Point Capital, LP has disclosed SNDX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Lion Point Capital, LP's current position in SNDX?

As of Q2 2026, Lion Point Capital, LP holds 36.00K shares of SNDX (SYNDAX PHARMACEUTICALS INC), valued at $786.96K, representing 3.76% of its reported portfolio and ranking #9.

Has Lion Point Capital, LP been buying or selling SNDX?

In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in SNDX. The position peaked in Q1 2024 at 65.00K shares.

Which other funds hold SNDX?

Other major institutional holders of SNDX include Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Eversept Partners, LP, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.